Astrazeneca jumped 7.6% as the Company received permission from the Drug Controller General of India to market Olaparib tablets in India. The tablet helps in the treatment of ovarian and breast cancer. As a result, the stock hit a new high and it is currently trading 48% above its pivot price of Rs 1,245.00.
